Pfizer Inc. (PFE) Current Ratio: 1.16
Is Pfizer Inc.’s current ratio high or low?
Pfizer Inc.'s current ratio of 1.16 is in line with its 5-year average of 1.20, around the middle of its 5-year range (0.91–1.40).
The current ratio for Pfizer Inc. (PFE) is 1.16 as of Wednesday, June 10, 2026. It is below its 12-month average by 0.43% (1.17).
PFE Current Ratio Chart
PFE Average Current Ratio Chart
PFE Current vs Average Current Ratio Chart
PFE Current Ratio Metrics
CURRENT RATIO
1.16
CURRENT RATIO AVG TTM
1.17
CURRENT RATIO AVG 3Y
1.11
CURRENT RATIO AVG 5Y
1.20
CURRENT RATIO AVG 10Y
1.25
CURRENT RATIO AVG 15Y
1.57
CURRENT RATIO AVG 20Y
1.63
CURRENT VS TTM AVG
-0.43%
CURRENT VS 3Y AVG
+4.04%
CURRENT VS 5Y AVG
-3.47%
CURRENT VS 10Y AVG
-7.20%
CURRENT VS 15Y AVG
-26.20%
CURRENT VS 20Y AVG
-28.81%
PFE Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | — | 1.16 | 1.17 | 1.11 | 1.20 |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 4.87 | 4.47 | 4.53 | 5.01 |
| Gilead Sciences, Inc. (GILD) | $151.21B | 1.68 | 1.64 | 1.50 | 1.45 |
| Abbott Laboratories (ABT) | $154.66B | 1.58 | 1.63 | 1.63 | 1.68 |
| Danaher Corporation (DHR) | $130.25B | 1.87 | 1.64 | 1.71 | 1.69 |
| CVS Health Corporation (CVS) | $125.16B | 0.84 | 0.82 | 0.86 | 0.88 |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 1.26 | 1.25 | 1.30 | 1.38 |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 1.89 | 1.77 | 1.69 | 1.74 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 2.90 | 2.79 | 3.60 | 3.87 |
| Amgen Inc. (AMGN) | $183.75B | 1.14 | 1.20 | 1.36 | 1.48 |
Liquidity Analysis
Current Ratio
1.16
Quick Ratio
0.87
Pfizer Inc. Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Current Ratio FAQ
- What is the current ratio for Pfizer Inc. (PFE)?
- The current ratio for PFE stock is 1.16.
- Is Pfizer Inc.'s current ratio high or low?
- Pfizer Inc.'s current ratio of 1.16 is in line with its 5-year average of 1.20, around the middle of its 5-year range (0.91–1.40).
- What is the TTM average current ratio for Pfizer Inc. (PFE)?
- The TTM average current ratio for PFE stock is 1.17.
- What is the 3Y average current ratio for Pfizer Inc. (PFE)?
- The 3Y average current ratio for PFE stock is 1.11.
- What is the 5Y average current ratio for Pfizer Inc. (PFE)?
- The 5Y average current ratio for PFE stock is 1.20.
- What is the 10Y average current ratio for Pfizer Inc. (PFE)?
- The 10Y average current ratio for PFE stock is 1.25.
- What is the 15Y average current ratio for Pfizer Inc. (PFE)?
- The 15Y average current ratio for PFE stock is 1.57.
- What is the 20Y average current ratio for Pfizer Inc. (PFE)?
- The 20Y average current ratio for PFE stock is 1.63.
Pfizer Inc. Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 1.16 |
| 2024-12-31 | 1.17 |
| 2023-12-31 | 0.91 |
| 2022-12-31 | 1.22 |
| 2021-12-31 | 1.40 |
| 2020-12-31 | 1.35 |
| 2019-12-31 | 0.88 |
| 2018-12-31 | 1.57 |
| 2017-12-31 | 1.35 |
| 2016-12-31 | 1.25 |
| 2015-12-31 | 1.49 |
| 2014-12-31 | 2.67 |
| 2013-12-31 | 2.41 |
| 2012-12-31 | 2.15 |
| 2011-12-31 | 2.06 |
| 2010-12-31 | 2.11 |
| 2009-12-31 | 1.66 |
| 2008-12-31 | 1.59 |
| 2007-12-31 | 2.15 |
| 2006-12-31 | 2.20 |
| 2005-12-31 | 1.47 |
| 2004-12-31 | 1.50 |
| 2003-12-31 | 1.26 |
| 2002-12-31 | 1.34 |
| 2001-12-31 | 1.35 |
| 2000-12-31 | 1.43 |
| 1999-12-31 | 1.22 |
| 1998-12-31 | 1.38 |
| 1997-12-31 | 1.29 |
| 1996-12-31 | 1.15 |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla